3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
Specimen Handling
7
Cisplatin
7
pembrolizumab
6
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Human Papillomavirus DNA Tests
4
Fulvestrant
4
Colposcopy
4
Paclitaxel
3
Carboplatin
3
Bevacizumab
3
palbociclib
2
lenvatinib
2
Surveys and Questionnaires
2
Radiotherapy, Intensity-Modulated
2
Radiation Dose Hypofractionation
2
Radiation
2
Platinum
2
Magnetic Resonance Imaging
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Congresses as Topic
2
Brachytherapy
2
Biopsy
2
Axitinib
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
1,2-diaminocyclohexaneplatinum II citrate
2
ulixertinib
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Imlunestrant
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled